Skip to main content
Clinical Trials/NCT05620056
NCT05620056CompletedNot Applicable

A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)

West China Hospital1 site in 1 country564,760 target enrollmentStarted: January 1, 2013Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
564,760
Locations
1
Primary Endpoint
congenital malformations

Study Overview

Brief Summary

The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes.

Detailed Description

The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes. The main goal of the study aims to monitor and evaluate the safety of drug use through the pregnancy life course in the Chinese setting. The DEEP cohort is developed primarily based on the population-based data platforms in Xiamen, a municipal city of 5 million population in southeast China. Based on these data platforms, a pregnancy-centered registry was developed that documented health care services and outcomes in the maternal and other departments. For identifying drug uses, a drug prescription database was specifically developed by using electronic healthcare records documented in the platforms across the primary, secondary and tertiary hospitals. By linking the pregnancy registry and prescription database through a unique identifier, the DEEP cohort was developed. All the pregnant women and their offspring in Xiamen are provided with health care and followed up according to standard protocols in the region, including antenatal care, delivery care, postpartum follow-up and childhood follow-ups. The primary adverse outcomes - congenital malformations - are collected using a standardized Case Report Form.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
14 Years to 65 Years (Child, Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Pregnant women who registered at the Maternal and Child Health Management Platform in Xiamen.

Exclusion Criteria

  • Not provided

Arms & Interventions

drug exposure

chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs

Intervention: chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs (Drug)

Outcomes

Primary Outcomes

congenital malformations

Time Frame: up to 42 days after delivery

Number of births with congenital malformations

Secondary Outcomes

  • preterm birth(up to 37 gestational weeks)
  • low birth weight(Immediately after delivery)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Sun Xin

Director of Chinese Evidence-based Medicine Center

West China Hospital

Study Sites (1)

Loading locations...

Similar Trials